Alphamab Oncology (9966.HK)

HKD 7.85

(21.52%)

EBITDA Summary of Alphamab Oncology

Alphamab Oncology's latest annual EBITDA in 2023 was -129.29 Million CNY , up 67.0% from previous year.
Alphamab Oncology's latest quarterly EBITDA in 2024 Q2 was -55.62 Million CNY , down 0.0% from previous quarter.
Alphamab Oncology reported an annual EBITDA of -391.82 Million CNY in 2022, down -1.22% from previous year.
Alphamab Oncology reported an annual EBITDA of -358.13 Million CNY in 2021, up 0.86% from previous year.
Alphamab Oncology reported a quarterly EBITDA of -99.02 Million CNY for 2023 Q2, down 0.0% from previous quarter.
Alphamab Oncology reported a quarterly EBITDA of N/A for 2023 FY, up 67.0% from previous quarter.

Annual EBITDA Chart of Alphamab Oncology (2023 - 2017)

Historical Annual EBITDA of Alphamab Oncology (2023 - 2017)

Year	EBITDA	EBITDA Growth
2023	-129.29 Million CNY	67.0%
2022	-391.82 Million CNY	-1.22%
2021	-358.13 Million CNY	0.86%
2020	-390.46 Million CNY	52.23%
2019	-277.57 Million CNY	-553.13%
2018	-91.93 Million CNY	-94.62%
2017	-64.92 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	-55.62 Million CNY	0.0%
2023 Q2	-99.02 Million CNY	0.0%
2023 FY	- CNY	67.0%
2023 Q4	-168.52 Million CNY	0.0%
2022 Q4	-186 Million CNY	0.0%
2022 FY	- CNY	-1.22%
2022 Q2	-205.82 Million CNY	0.0%
2021 Q2	-256.49 Million CNY	0.0%
2021 Q4	-130.6 Million CNY	0.0%
2021 FY	- CNY	0.86%
2020 FY	- CNY	52.23%
2020 Q4	-224.71 Million CNY	0.0%
2020 Q2	-165.75 Million CNY	0.0%
2019 FY	- CNY	-553.13%
2019 Q4	-200.05 Million CNY	0.0%
2019 Q2	-77.51 Million CNY	62.07%
2019 Q1	-204.34 Million CNY	-261.54%
2018 Q1	-35.44 Million CNY	0.0%
2018 Q2	-35.41 Million CNY	0.08%
2018 FY	- CNY	-94.62%
2018 Q4	-56.52 Million CNY	0.0%
2017 Q2	-8.13 Million CNY	0.0%
2017 Q1	-8.13 Million CNY	0.0%
2017 FY	- CNY	0.0%
2017 Q4	-35.44 Million CNY	0.0%
2016 Q4	-8.13 Million CNY	0.0%

Peer EBITDA Comparison of Alphamab Oncology

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	241.719%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	126.561%